IMU in the drivers seat...don't be fooled., page-137

Sure @Bioalltheway I'll be happy if and when when we're back at 33c.

I think most holders here have much higher targets than that though. If our IP ends up being as valuable as people are hoping, we'll be looking at share price targets closer to $3.30 than 33c.

I don't know the probability of us getting to $3 in the next few years, but my guess is that it is less than 50%. If it was more than that, big pharma would have already snapped us up. Let's face it, they know what we have, they've seen our clinical results to date, they have more than enough spare cash to acquire what we have, yet they haven't. They are also far better qualified to value our IP than you, me or any other poster here.